Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

PHASE2CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

May 29, 2014

Primary Completion Date

April 30, 2025

Study Completion Date

May 26, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide

DRUG

Dexamethasone

DRUG

Daratumumab

Trial Locations (49)

10467

Local Institution - 149, The Bronx

12801

Local Institution - 129, Glens Falls

21157

Local Institution - 103, Westminster

27705

Local Institution - 130, Durham

32256

Local Institution - 145, Jacksonville

32804

Local Institution - 127, Orlando

33028

Local Institution - 133, Pembroke Pines

33705

Local Institution - 136, St. Petersburg

37203

Local Institution - 131, Nashville

37404

Local Institution - 135, Chattanooga

40207

Local Institution - 124, Louisville

44106

Local Institution - 123, Cleveland

44111

Local Institution - 121, Cleveland

44124

Local Institution - 122, Mayfield Heights

44195

Local Institution - 115, Cleveland

48236

Local Institution - 146, Gross Pointe

63110

Local Institution - 110, St Louis

64111

Local Institution - 102, Kansas City

66205

Local Institution - 134, Fairway

66606

Local Institution - 142, Topeka

75093

Local Institution - 143, Plano

79410

Local Institution - 128, Lubbock

80218

Local Institution - 138, Denver

85724

Local Institution - 126, Tucson

90603

Local Institution - 108, Whittier

94523

Local Institution - 104, Pleasant Hill

99218

Local Institution - 106, Spokane

94904-2007

Local Institution - 137, Greenbrae

90095-1670

Local Institution - 109, Los Angeles

06902

Local Institution - 120, Stamford

07018

Local Institution - 118, East Orange

07601

Local Institution - 101, Hackensack

17033-0850

Local Institution - 107, Hershey

T2N 2T9

Local Institution - 113, Calgary

V3V 1Z2

Local Institution - 144, Surrey

V5Z 4E6

Local Institution - 114, Vancouver

E1C 8X3

Local Institution - 139, Moncton

A1B3V6

Local Institution - 140, St. John's

M5G 2M9

Local Institution - 112, Toronto

Local Institution - 148, Toronto

H3A 1A1

Local Institution - 117, Montreal

810-8563

Local Institution - 205, Fukuoka

296-8602

Local Institution - 208, Kamogawa

602-8566

Local Institution - 204, Kyoto

467-8602

Local Institution - 202, Nagoya

701-1192

Local Institution - 203, Okayama

377-0280

Local Institution - 206, Shibukawa-shi, Gunma-ken

441-8570

Local Institution - 207, Toyohashi

00927

Local Institution - 119, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01946477 - Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting | Biotech Hunter | Biotech Hunter